Publication List Prof. Hammerer

 

1:  Merseburger AS, Hammerer P, Rozet F, Roumeguère T, Caffo O, da Silva FC, Alcaraz A. Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy? World J Urol. 2014 Sep 27. [Epub ahead of print]

2:  Haider A, Zitzmann M, Doros G, Isbarn H, Hammerer P, Yassin A. Incidence of Prostate Cancer in Hypogonadal Men Receiving Testosterone Therapy: Observations from Five Year-median Follow-up of Three Registries. J Urol. 2014 Jun 26. pii: S0022-5347(14)03885-3.

3:  Yassin DJ, Doros G, Hammerer PG, Yassin AA. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J  Sex Med. 2014 Jun;11(6):1567-76.

4:  Yassin DJ, Yassin AA, Hammerer PG. Combined testosterone and vardenafil treatment for restoring erectile function in hypogonadal patients who failed to respond to testosterone therapy alone. J Sex Med. 2014 Feb;11(2):543-52.

5:  Yassin DJ, El Douaihy Y, Yassin AA, Kashanian J, Shabsigh R, Hammerer PG. Lower urinary tract symptoms improve with testosterone replacement therapy in men with late-onset hypogonadism: 5-year prospective, observational and longitudinal  registry study. World J Urol. 2014 Aug;32(4):1049-54.

6:  Miller K, Hammerer P, Eichenauer R, Geiges G, Lehmann J, Rodemer G, Ruessel C, Rulf W, Suttmann H, Wolff JM. [Value of intermittent androgen deprivation in the context of the current data situation]. Aktuelle Urol. 2013 Jul;44(4):271-6..

7:  Heidenreich A, Hammerer P. [Nerve sparing radical retropubic prostatectomy and lymph node excision in prostate carcinoma]. Aktuelle Urol. 2013 May;44(3):223-42.

8:  Hammerer P, Madersbacher S. Reply: Landmarks in hormonal therapy for prostate cancer. BJU Int. 2013 Mar;111(3):E13-5.

9:  Slojewski M, Safranow K, Jakubowska K, Olszewska M, Pawlik A, Juzyszyn Z, Drozdzik M, Chlubek D, Hammerer P, Sikorski A. Can we predict urinary stone composition based on an analysis of microelement concentration in the hair and urine? Adv Clin Exp Med. 2012 Jul-Aug;21(4):469-75.

10: Hammerer P, Madersbacher S. Landmarks in hormonal therapy for prostate cancer. BJU Int. 2012 Oct;110 Suppl 1:23-9.

11:  Braunwarth H, Brill FH, Hegeholz D, Hammerer P. [The influence of viscosity of synthetic urine on the flow rate through catheters]. Urologe A. 2012 Mar;51(3):403-8.

12:  Madersbacher S, Alcaraz A, Emberton M, Hammerer P, Ponholzer A, Schröder FH, Tubaro A. The influence of family history on prostate cancer risk: implications for clinical management. BJU Int. 2011 Mar;107(5):716-21.

13:  Börgermann C, Loertzer H, Hammerer P, Fornara P, Graefen M, Rübben H.[Problems, objective, and substance of early detection of prostate cancer]. Urologe A. 2010 Feb;49(2):181-9

14:  Zugor V, Labanaris AP, Rezaei-Jafari MR, Hammerer P, Dembowski J, Witt J, Wucherpfennig W. TVT vs. TOT: a comparison in terms of continence results, complications and quality of life after a median follow-up of 48 months. Int Urol Nephrol. 2010 Dec;42(4):915-20.

15:  Börgermann C, Loertzer H, Luboldt HJ, Hammerer P, Fornara P, Graefen M, Rübben H. [PSA--Quo vadis?]. Urologe A. 2009 Sep;48(9):1008, 1010, 1012-4,

16:  Jeron A, Pfoertner S, Bruder D, Geffers R, Hammerer P, Hofmann R, Buer J, Schrader AJ. Frequency and gene expression profile of regulatory T cells in renal cell carcinoma. Tumour Biol. 2009;30(3):160-70.

17:  Montorsi F, Alcaraz A, Desgrandchamps F, Hammerer P, Schröder F, Castro R. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. Prostate. 2009 Jun 1;69(8):895-907. Review. PubMed PMID: 19267353.

18:  Alcaraz A, Hammerer P, Tubaro A, Schröder FH, Castro R. Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol. 2009 Apr;55(4):864-73. Epub 2008 Nov 21. Review. PubMed PMID: 19027219.

19:  Boccon-Gibod L, Hammerer P, Madersbacher S, Mottet N, Prayer-Galetti T, Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int. 2007 Oct;100(4):738-43. Epub 2007 Jul 23. Review. PubMed PMID: 17662079.

20:  Djavan B, Ravery V, Rocco B, Zlotta A, Brausi M, Margreiter M, Hammerer P, Kaisary A, Anagnostou T, Romics I, Dobronski P, De Cobelli O, Marberger M. European Study of Radical Prostatectomy: time trends in Europe, 1993-2005. BJU Int. 2007 Jul;100 Suppl 2:22-5. Review. PubMed PMID: 17594353.

21:  Börgermann C, Sieverding M, Fornara P, Graefen M, Hammerer P, Semjonow A, Schröder F, Rübben H. [PSA 2010--the beginning of a new era in early detection of prostate cancer]. Urologe A. 2006 Sep;45 Suppl 4:127-33. German. PubMed PMID: 16941115.

22:  Tilki D, Irmak S, Oliveira-Ferrer L, Hauschild J, Miethe K, Atakaya H, Hammerer P, Friedrich MG, Schuch G, Galalae R, Stief CG, Kilic E, Huland H, Ergun S. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene. 2006 Aug 17;25(36):4965-74. Epub 2006 Mar 27. PubMed PMID: 16568082.

23:  Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int. 2006 Jul;98(1):20-7. Epub 2006 Mar 23. Review. PubMed PMID: 16566812.

24:  Hammerer PG, Kattan MW, Mottet N, Prayer-Galetti T. Using prostate-specific antigen screening and nomograms to assess risk and predict outcomes in the management of prostate cancer. BJU Int. 2006 Jul;98(1):11-9. Epub 2006 Mar 23. Review. PubMed PMID: 16566811.

25:  Heidenreich A, Hammerer P. [Nerve-sparing radical retropubic prostatectomy and pelvic lymph node excision in prostatic carcinoma]. Aktuelle Urol. 2005 Sep;36(5):439-56; quiz 457-9. German. PubMed PMID: 16163607.

26:  Keller T, Butz H, Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P,  Stephan C, Jung K. Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. Clin Chem. 2005 Mar;51(3):532-9. PubMed PMID: 15738515.

27:  Augustin H, Erbersdobler A, Hammerer PG, Graefen M, Huland H. Prostate cancers in the transition zone: Part 2; clinical aspects. BJU Int. 2004 Dec;94(9):1226-9. Review. PubMed PMID: 15610094.

28:  Hautmann S, Friedrich MG, Fernandez S, Steuber T, Hammerer P, Braun PM, Jünemann KP, Huland H. Extracorporeal shockwave lithotripsy compared with ureteroscopy for the removal of small distal ureteral stones. Urol Int. 2004;73(3):238-43. PubMed PMID: 15539843.

29:  Hammerer P. [Pro and contra -- adjuvant therapy in locoregional advanced prostatic carcinoma after radical prostatectomy]. Aktuelle Urol. 2004 Sep;35(5):371-2. German. PubMed PMID: 15384001.

30:  Boccon-Gibod L, Djavan WB, Hammerer P, Hoeltl W, Kattan MW, Prayer-Galetti T, Teillac P, Tunn UW. Management of prostate-specific antigen relapse in prostate cancer: a European Consensus. Int J Clin Pract. 2004 Apr;58(4):382-90. Review. Erratum in: Int J Clin Pract. 2004 Jun;58(6):648. PubMed PMID: 15161124.

31:  Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A, Huland  H. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. Eur Urol. 2004 Jun;45(6):737-43. PubMed PMID: 15149745.

32:  Hammerer PG, Augustin H, Blonski J, Graefen M, Haese A, Erbersdobler A, Daghofer F, Huland H. [Influence of transrectal endosonography on the clinical staging of impalpable prostate cancer. A controversy over the TNM system]. Urologe A. 2004 Mar;43(3):307-12. German. PubMed PMID: 15045191.

33:  Röpke A, Erbersdobler A, Hammerer P, Palisaar J, John K, Stumm M, Wieacker P. Gain of androgen receptor gene copies in primary prostate cancer due to X chromosome polysomy. Prostate. 2004 Apr 1;59(1):59-68. PubMed PMID: 14991866.

34:  Augustin H, Hammerer PG. Disease recurrence after radical prostatectomy. Contemporary diagnostic and therapeutical strategies. Minerva Urol Nefrol. 2003 Dec;55(4):251-61. Review. PubMed PMID: 14765017.

35:  Cagiannos I, Karakiewicz P, Graefen M, Eastham JA, Ohori M, Rabbani F, Reuter V, Wheeler T, Kupelian P, Klein E, Huland H, Hammerer PG, Erbersdobler A, Schroeder F, Wildhagen M, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Morash CG, Scardino PT, Kattan MW. Is year of radical prostatectomy  a predictor of outcome in prostate cancer? J Urol. 2004 Feb;171(2 Pt 1):692-6. PubMed PMID: 14713788.

36:  Hammerer P. pT0 after radical prostatectomy: overtreatment for insignificant  prostate cancer? Eur Urol. 2004 Jan;45(1):35. PubMed PMID: 14667512.

37:  Graefen M, Ohori M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Erbersdobler A, Henke RP, Huland H, Wheeler TM, Slawin K, Scardino PT, Kattan MW. Assessment of the enhancement in predictive accuracy provided by systematic biopsy in predicting outcome for clinically localized prostate cancer. J Urol. 2004 Jan;171(1):200-3. PubMed PMID: 14665876.

38: Augustin H, Hammerer PG, Graefen M, Palisaar J, Daghofer F, Huland H, Erbersdobler A. Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy. J Cancer Res Clin Oncol. 2003 Nov;129(11):662-8. Epub 2003 Sep 26. PubMed PMID: 14513368.

39  Graefen M, Hammerer PG, Haese A, Huland H. [Indications for and results of radical prostatectomy]. Urologe A. 2003 Sep;42(9):1203-11. Review. German. PubMed PMID: 14504753.

40:  Lein M, Kwiatkowski M, Semjonow A, Luboldt HJ, Hammerer P, Stephan C, Klevecka V, Taymoorian K, Schnorr D, Recker F, Loening SA, Jung K. A multicenter  clinical trial on the use of complexed prostate specific antigen in low prostate  specific antigen concentrations. J Urol. 2003 Oct;170(4 Pt 1):1175-9. PubMed PMID: 14501719.

41:  Augustin H, Graefen M, Palisaar J, Blonski J, Erbersdobler A, Daghofer F, Huland H, Hammerer PG. Prognostic significance of visible lesions on transrectal  ultrasound in impalpable prostate cancers: implications for staging. J Clin Oncol. 2003 Aug 1;21(15):2860-8. PubMed PMID: 12885802.

42:  Augustin H, Hammerer PG, Blonski J, Graefen M, Palisaar J, Daghofer F, Huland H, Erbersdobler A. Zonal location of prostate cancer: significance for disease-free survival after radical prostatectomy? Urology. 2003 Jul;62(1):79-85. PubMed PMID: 12837427.

43: Kuczyk M, Turkeri L, Hammerer P, Ravery V; European Society for Oncological Urology. Is there a role for bladder preserving strategies in the treatment of muscle-invasive bladder cancer? Eur Urol. 2003 Jul;44(1):57-64. Review. PubMed PMID: 12814676.

44:  Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Cagiannos I, Scardino PT, Kattan MW, Huland H. [Can nomograms derived in the U.S. applied to German patients? A study about the validation of preoperative nomograms predicting the risk of recurrence  after radical prostatectomy]. Urologe A. 2003 May;42(5):685-92. Epub 2003 Jan 17. German. PubMed PMID: 12750804.

45:  Augustin H, Hammerer PG, Graefen M, Erbersdobler A, Blonski J, Palisaar J, Daghofer F, Huland H. Insignificant prostate cancer in radical prostatectomy specimen: time trends and preoperative prediction. Eur Urol. 2003 May;43(5):455-60. PubMed PMID: 12705986.

46: Augustin H, Erbersdobler A, Graefen M, Jaekel T, Haese A, Huland H, Hammerer  PG. Differences in biopsy features between prostate cancers located in the transition and peripheral zone. BJU Int. 2003 Apr;91(6):477-81. PubMed PMID: 12656897.

47: Augustin H, Erbersdobler A, Graefen M, Fernandez S, Palisaar J, Huland H, Hammerer P. Biochemical recurrence following radical prostatectomy: a comparison  between prostate cancers located in different anatomical zones. Prostate. 2003 Apr 1;55(1):48-54. PubMed PMID: 12640660.

48:  Erbersdobler A, Huhle S, Palisaar J, Graefen M, Hammerer P, Noldus J, Huland H. Pathological and clinical characteristics of large prostate cancers predominantly located in the transition zone. Prostate Cancer Prostatic Dis. 2002;5(4):279-84. PubMed PMID: 12627212.

49: Haese A, Chaudhari M, Miller MC, Epstein JI, Huland H, Palisaar J, Graefen M, Hammerer P, Poole EC, O'Dowd GJ, Partin AW, Veltri RW. Quantitative biopsypathology for the prediction of pathologically organ-confined prostate carcinoma: a multiinstitutional validation study. Cancer. 2003 Feb 15;97(4):969-78. PubMed PMID: 12569595.

50:  Friedrich MG, Hellstern A, Toma MI, Hammerer P, Huland H. Are false-positive  urine markers for the detection of bladder carcinoma really wrong or do they predict tumor recurrence? Eur Urol. 2003 Feb;43(2):146-50; discussion 150-1. PubMed PMID: 12565772.

51:  Augustin H, Hammerer P, Graefen M, Palisaar J, Noldus J, Fernandez S, Huland  H. Intraoperative and perioperative morbidity of contemporary radical retropubic  prostatectomy in a consecutive series of 1243 patients: results of a single center between 1999 and 2002. Eur Urol. 2003 Feb;43(2):113-8. PubMed PMID: 12565767.

52:  Graefen M, Augustin H, Karakiewicz PI, Hammerer PG, Haese A, Palisaar J, Blonski J, Fernandez S, Erbersdobler A, Huland H. Can predictive models for prostate cancer patients derived in the United States of America be utilized in European patients? A validation study of the Partin tables. Eur Urol. 2003 Jan;43(1):6-10; discussion 11. PubMed PMID: 12507538.

53:  Hammerer P, Graefen M, Henke RP, Haese A, Huland E, Huland H. Ratio free/total PSA (%f-PSA) in men with total PSA 0.5-3 ng/ml: improvement for prostate cancer detection? Prostate Cancer Prostatic Dis. 2000 Dec;3(S1):S19. PubMed PMID: 12497129.

54:  Graefen M, Pichlmeier U, Hammerer PG, Haese A, Butz K, Erbersdobler A, Henke RP, Huland H. A validated strategy to select patients for a nerve-sparing radical prostatectomy. Prostate Cancer Prostatic Dis. 2000 Dec;3(S1):S18. PubMed PMID: 12497128.

55:  Erbersdobler A, Graefen M, Wullbrand A, Hammerer P, Henke RP. Allelic losses at 8p, 10q, 11p, 13q, 16q, 17p, and 18q in prostatic carcinomas: The impact of zonal location, Gleason grade, and tumour multifocality. Prostate Cancer Prostatic Dis. 1999 Jul;2(4):204-210. PubMed PMID: 12496779.

56:  Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Fernandez S, Noldus J, Erbersdobler A, Huland H, Scardino PT, Kattan MW. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol. 2002 Jul-Aug;7(4):141-6. PubMed PMID: 12474529.

57:  Steuber T, Nurmikko P, Haese A, Pettersson K, Graefen M, Hammerer P, Huland H, Lilja H. Discrimination of benign from malignant prostatic disease by selective measurements of single chain, intact free prostate specific antigen. J  Urol. 2002 Nov;168(5):1917-22. Erratum in: J Urol 2003 Jan;169(1):295. PubMed PMID: 12394676.

58:  Djavan B, Remzi M, Zlotta AR, Ravery V, Hammerer P, Reissigl A, Dobronski P,  Kaisary A, Marberger M. Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the
prospective multicenter European trial. Urology. 2002 Oct;60(4 Suppl 1):4-9. PubMed PMID: 12384156.

59:  Noldus J, Michl U, Graefen M, Haese A, Hammerer P, Huland H. Patient-reported sexual function after nerve-sparing radical retropubic prostatectomy. Eur Urol. 2002 Aug;42(2):118-24. PubMed PMID: 12160581.

60:  Graefen M, Karakiewicz PI, Cagiannos I, Quinn DI, Henshall SM, Grygiel JJ, Sutherland RL, Stricker PD, Klein E, Kupelian P, Skinner DG, Lieskovsky G, Bochner B, Huland H, Hammerer PG, Haese A, Erbersdobler A, Eastham JA, de Kernion J, Cangiano T, Schröder FH, Wildhagen MF, van der Kwast TH, Scardino PT, Kattan MW. International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol. 2002 Aug 1;20(15):3206-12. PubMed PMID: 12149292.

61:  Palisaar RJ, Graefen M, Karakiewicz PI, Hammerer PG, Huland E, Haese A, Fernandez S, Erbersdobler A, Henke RP, Huland H. Assessment of clinical and pathologic characteristics predisposing to disease recurrence following radical prostatectomy in men with pathologically organ-confined prostate cancer. Eur Urol. 2002 Feb;41(2):155-61. PubMed PMID: 12074402.

62:  Huland H, Graefen M, Haese A, Hammerer PG, Palisaar J, Pichlmeier U, Henke RP, Erbersdobler A, Huland E, Lilja H. Prediction of tumor heterogeneity in localized prostate cancer. Urol Clin North Am. 2002 Feb;29(1):213-22. Review. PubMed PMID: 12109347.

63:  Erbersdobler A, Fritz H, Schnöger S, Graefen M, Hammerer P, Huland H, Henke RP. Tumour grade, proliferation, apoptosis, microvessel density, p53, and bcl-2 in prostate cancers: differences between tumours located in the transition zone and in the peripheral zone. Eur Urol. 2002 Jan;41(1):40-6. PubMed PMID: 11999464.

64:  Cagiannos I, Graefen M, Karakiewicz PI, Ohori M, Eastham JA, Rabbani F, Fair W, Wheeler TM, Hammerer PG, Haese A, Erbersdobler A, Huland H, Scardino PT, Kattan MW. Analysis of clinical stage T2 prostate cancer: do current subclassifications represent an improvement? J Clin Oncol. 2002 Apr 15;20(8):2025-30. PubMed PMID: 11956261.

65:  Ergün S, Kilic N, Wurmbach JH, Ebrahimnejad A, Fernando M, Sevinc S, Kilic E, Chalajour F, Fiedler W, Lauke H, Lamszus K, Hammerer P, Weil J, Herbst H, Folkman J. Endostatin inhibits angiogenesis by stabilization of newly formed endothelial  tubes. Angiogenesis. 2001;4(3):193-206. PubMed PMID: 11911017.

66:  Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, Huland E, Scardino PT, Kattan MW, Huland H. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy. J Urol. 2002 Mar;167(3):1306-9. PubMed PMID:
11832719.

67:  Conrad S, Graefen M, Pichlmeier U, Henke RP, Erbersdobler A, Hammerer PG, Huland H. Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol. 2002 Feb;167(2 Pt 1):521-5. PubMed PMID: 11792910.

68:  Friedrich MG, Blind C, Milde-Langosch K, Erbersdobler A, Conrad S, Löning T,  Hammerer P, Huland H. Frequent p16/MTS1 inactivation in early stages of urothelial carcinoma of the bladder is not associated with tumor recurrence. Eur  Urol. 2001 Nov;40(5):518-24. PubMed PMID: 11752859.

69:  Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D, Loening SA. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis. Prostate. 2001 May 1;47(2):77-84. PubMed PMID: 11340629.

70:  Prange W, Erbersdobler A, Hammerer P, Graefen M, Hautmann SH, Hautmann RE, Huland H, Henke RP. High-grade prostatic intraepithelial neoplasia in cystoprostatectomy specimens. Eur Urol. 2001 Apr;39 Suppl 4:30-1. PubMed PMID: 11340284.

71:  Hammerer P, Graefen M, Henke RP, Haese A, Palisaar J, Huland E, Huland H. Analysis of molecular isoforms of PSA and their ratios in men with PSA-relapse after radical prostatectomy. Anticancer Res. 2000 Nov-Dec;20(6D):5253-5. PubMed PMID: 11326705.

72:  Wurmbach JH, Hammerer P, Sevinc S, Huland H, Ergün S. The expression of angiopoietins and their receptor Tie-2 in human prostate carcinoma. Anticancer Res. 2000 Nov-Dec;20(6D):5217-20. PubMed PMID: 11326698.

73:  Noldus J, Michl U, Graefen M, Haese A, Hammerer P, Fernandez S, Huland H. [Nerve-sparing radical retropubic prostatectomy. Results of a patient survey]. Urologe A. 2001 Mar;40(2):102-6. German. PubMed PMID: 11315583.

74:  Prange W, Erbersdobler A, Hammerer P, Graefen M, Hautmann SH, Hautmann RE, Huland H, Henke RP. Significance of high-grade prostatic intraepithelial neoplasia in needle biopsy specimens. Urology. 2001 Mar;57(3):486-90. PubMed PMID: 11248625.

75:  Friedrich MG, Riethdorf S, Erbersdobler A, Tiemer C, Schwaibold H, Sölter JK, Huland E, Riethdorf L, Conrad S, Hammerer PG, Huland H. Relevance of p53 gene alterations for tumor recurrence in patients with superficial transitional cell carcinoma of the bladder. Eur Urol. 2001 Feb;39(2):159-66. PubMed PMID: 11223675.

76:  Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K, Erbersdobler A, Henke RP, Michl U, Fernandez S, Huland H. A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol. 2001 Mar;165(3):857-63. PubMed PMID: 11176486.

77:  Hammerer P, Graefen M, Steuber T, Huland H. [Chemoprevention of prostatic carcinoma]. Urologe A. 2000 Jul;39(4):304-8. Review. German. PubMed PMID: 10957770.

78:  Hammerer P, Semjonow A. [10 years PSA--chemoprevention]. Urologe A. 2000 Jul;39(4):302-3. German. PubMed PMID: 10957769.

79:  Hilz H, Graefen M, Noldus J, Hammerer P, Knabbe C, Huland E, Huland H. Advanced prostate cancer is associated with a decrease in serum luteinizing hormone. Eur Urol. 2000 Sep;38(3):243-9. PubMed PMID: 10940695.

80:  Graefen M, Hammerer P, Haese A, Huland H. [Therapeutic options in hormone refractory prostate carcinoma]. Urologe A. 2000 May;39(3):267-73. Review. German. PubMed PMID: 10872254.

81:  Noldus J, Graefen M, Haese A, Henke RP, Hammerer P, Huland H. Stage migration in clinically localized prostate cancer. Eur Urol. 2000 Jul;38(1):74-8. PubMed PMID: 10859445.

82:  Graefen M, Hammerer P, Noldus J, Haese A, Pichelmeier U, Erbersdobler A, Henke H, Conrad S, Fernandez S, Huland H. [Prognostic markers for prostate cancer]. Urologe A. 2000 Jan;39(1):14-21. Review. German. PubMed PMID: 10663191.

83:  Heinzer H, Hammerer PG, Huland H. Anatomy and physiology of the male urethral sphincter and its preservation in prostatic surgery. Urol Res. 1999 Dec;27(6):404-8. Review. PubMed PMID: 10651127.

84:  Hilz H, Noldus J, Hammerer P, Buck F, Lück M, Huland H. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur Urol. 1999 Oct;36(4):286-92. PubMed PMID: 10473986.

85:  Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer P, Fernandez S, Conrad S, Henke R, Huland E, Huland H. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics. Eur Urol. 1999;36(1):21-30. PubMed PMID: 10364651.

86:  Haese A, Huland E, Graefen M, Hammerer P, Noldus J, Huland H. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy. J Urol. 1999 Apr;161(4):1206-11. PubMed PMID: 10081870.

87:  Terris MK, Hammerer PG, Nickas ME. Comparison of ultrasound imaging in patients undergoing transperineal and transrectal prostate ultrasound. Urology. 1998 Dec;52(6):1070-2. PubMed PMID: 9836556.

88:  Henke RP, Hammerer P, Graefen M, Erbersdobler A, Neumann M, Berger J, Huland  H. Interphase cytogenetic study of preoperative core biopsies for the prediction of early serum prostate specific antigen recurrence after radical prostatectomy of clinically localized prostate carcinoma. Cancer. 1998 Sep 1;83(5):977-88. PubMed PMID: 9731903.

89:  Conrad S, Graefen M, Pichlmeier U, Henke RP, Hammerer PG, Huland H. Systematic sextant biopsies improve preoperative prediction of pelvic lymph node  metastases in patients with clinically localized prostatic carcinoma. J Urol. 1998 Jun;159(6):2023-9. PubMed PMID: 9598511.

90:  Noldus J, Graefen M, Huland E, Busch C, Hammerer P, Huland H. The value of the ratio of free-to-total prostate specific antigen for staging purposes in previously untreated prostate cancer. J Urol. 1998 Jun;159(6):2004-7; discussion 2007-8. PubMed PMID: 9598507.

91:  Lange I, Hammerer P, Knabbe C, Graefen M, Schmahl M, Huland H. [Plasma TGF-beta1 concentrations in patients with prostate carcinoma or benign prostatic hyperplasia]. Urologe A. 1998 Mar;37(2):199-202. German. PubMed PMID: 9563135.

92:  Noldus J, Graefen M, Hammerer P, Henke RP, Huland H. [Development of tumor selection based on pathological stage in clinically localized prostate carcinoma]. Urologe A. 1998 Mar;37(2):195-8. German. PubMed PMID: 9563134.

93:  Graefen M, Hammerer P, Michl U, Noldus J, Haese A, Henke RP, Huland E, Huland H. Incidence of positive surgical margins after biopsy-selected nerve-sparing radical prostatectomy. Urology. 1998 Mar;51(3):437-42. PubMed PMID: 9510349.

94:  Hammerer P, Huland H. [Urodynamic changes after radical prostatectomy]. Urologe A. 1997 Nov;36(6):535-9. German. PubMed PMID: 9487589.

95:  Heinzer H, Hammerer P, Graefen M, Huland H. Thromboembolic complication rate  after radical retropubic prostatectomy. Impact of routine ultrasonography for the detection of pelvic lymphoceles and hematomas. Eur Urol. 1998;33(1):86-90. PubMed PMID: 9471046.

96:  Haese A, Graefen M, Noldus J, Hammerer P, Huland E, Huland H. Prostatic volume and ratio of free-to-total prostate specific antigen in patients with prostatic cancer or benign prostatic hyperplasia. J Urol. 1997 Dec;158(6):2188-92. PubMed PMID: 9366341.

97:  Erbersdobler A, Hammerer P, Huland H, Henke RP. Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. J Urol. 1997 Oct;158(4):1594-8. PubMed PMID: 9302180.

98:  Heinzer H, Graefen M, Noldus J, Hammerer P, Huland H. Early complication of anatomical radical retropubic prostatectomy: lessons from a single-center experience. Urol Int. 1997;59(1):30-3. PubMed PMID: 9313321.

99:  Noldus J, Hammerer P, Graefen M, Huland H. Surgical therapy for localized prostatic carcinoma. J Cancer Res Clin Oncol. 1997;123(3):180-4. PubMed PMID: 9119884.

100:  Hammerer P, Huland H. Urodynamic evaluation of changes in urinary control after radical retropubic prostatectomy. J Urol. 1997 Jan;157(1):233-6. PubMed
PMID: 8976260.

101:  Hammerer P, Michl U, Meyer-Moldenhauer WH, Huland H. Urethral closure pressure changes with age in men. J Urol. 1996 Nov;156(5):1741-3. PubMed PMID: 8863584.

102:  Huland H, Hammerer P, Henke RP, Huland E. Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal, examination prostate specific antigen and the results of 6 systematic biopsies. J Urol. 1996 Apr;155(4):1344-7. PubMed PMID: 8632570.

103:  Hammerer P, Henke RP, Hübner D, Huland H. [Preoperative assessment of tumor aggressiveness in localized prostatic carcinoma]. Urologe A. 1995 Sep;34(5):413-8. German. PubMed PMID: 7483160.

104:  Hammerer P, Hübner D, Gonnermann D, Huland H. [Perioperative and postoperative complications of pelvic lymphadenectomy and radical prostatectomy in 320 consecutive patients]. Urologe A. 1995 Jul;34(4):334-42. German. PubMed PMID: 7545846.

105:  Hammerer P, Huland H. [Value of determining prostate-specific antigen for early detection or prostatic carcinoma]. Urologe A. 1995 Jul;34(4):283-9. Review. German. PubMed PMID: 7545842.

106:  Hammerer P, Huland H. [Status of PSA determination for early detection of prostate carcinoma]. Versicherungsmedizin. 1995 Jun 1;47(3):83-6. Review. German. PubMed PMID: 7541925.

107:  Hammerer PG, McNeal JE, Stamey TA. Correlation between serum prostate specific antigen levels and the volume of the individual glandular zones of the human prostate. J Urol. 1995 Jan;153(1):111-4. PubMed PMID: 7526003.

108:  Hübner D, Henke RP, Hammerer P, Huland H. [Morphologic results of 106 consecutive radical prostatectomy specimen of patients with clinical stage B1-B3  (T2a-c) and histologically negative lymph nodes in the fossa obturatoria]. Urologe A. 1994 Nov;33(6):497-504. German. PubMed PMID: 7817447.

109:  Henke RP, Krüger E, Ayhan N, Hübner D, Hammerer P, Huland H. Immunohistochemical detection of p53 protein in human prostatic cancer. J Urol. 1994 Oct;152(4):1297-301. PubMed PMID: 8072122.

110:  Henke RP, Krüger E, Ayhan N, Hübner D, Hammerer P. Frequency and distribution of numerical chromosomal aberrations in prostatic cancer. Hum Pathol. 1994 May;25(5):476-84. PubMed PMID: 8200641.

111:  Hammerer PG. [Sonographic diagnosis of prostatic cancer]. Radiologe. 1994 Mar;34(3):116-21. Review. German. PubMed PMID: 7513895.

112:  Hammerer P, Huland H. Systematic sextant biopsies in 651 patients referred for prostate evaluation. J Urol. 1994 Jan;151(1):99-102. PubMed PMID: 7504750.

113:  Henke RP, Krüger E, Ayhan N, Hübner D, Hammerer P. Numerical chromosomal aberrations in prostate cancer: correlation with morphology and cell kinetics. Virchows Arch A Pathol Anat Histopathol. 1993;422(1):61-6. PubMed PMID: 7679850.

114:  Henke RP, Krüger E, Ayhan N, Hübner D, Hammerer P. [Significance of numerical chromosome aberrations in prostate cancer]. Verh Dtsch Ges Pathol. 1993;77:133-7. German. PubMed PMID: 7511271.

115:  Hammerer P, Loy V, Dieringer J, Huland H. Prostate cancer in nonurological patients with normal prostates on digital rectal examination. J Urol. 1992 Mar;147(3 Pt 2):833-6. PubMed PMID: 1371557.

116:  Hammerer P, Huland H, Sparenberg A. Digital rectal examination, imaging, and systematic-sextant biopsy in identifying operable lymph node-negative prostatic carcinoma. Eur Urol. 1992;22(4):281-7. PubMed PMID: 1283372.

117:  Hammerer P, Huland H. [Diagnosis of localized prostate cancer: screening and preoperative staging]. Urologe A. 1991 Nov;30(6):378-86. German. PubMed PMID: 1722921.

118:  Hammerer P. [Endosonography of the prostate]. Urologe A. 1991 Nov;30(6):370-7. Review. German. PubMed PMID: 1722920.

119:  Hammerer P, Huland H. [The diagnosis of prostatic carcinoma]. Fortschr Med. 1991 Sep 10;109(26):512-7. Review. German. PubMed PMID: 1723711.

120:  Sparenberg A, Hamm B, Hammerer P, Samberger V, Wolf KJ. [The diagnosis of bladder carcinomas by NMR tomography: an improvement with Gd-DTPA?]. Rofo. 1991 Aug;155(2):117-22. German. PubMed PMID: 1878537.

121:  Hammerer P, Huland H. [Anatomy and sonography of the prostate]. Urologe A. 1989 Nov;28(6):311-6. Review. German. PubMed PMID: 2481356.

122:  Huland H, Hammerer P. [Monoclonal antibodies in diagnosis and therapy]. Immun Infekt. 1989 Feb;17(1):28. Review. German. PubMed PMID: 2647624.

123:  Arndt R, Weiss M, Hammerer P, Huland H, Kruppa A, Krämer-Hansen H. Expression of immunoregulatory molecules on tubular cells and lymphocytes in fine-needle aspiration biopsy: early diagnostic marker for renal allograft rejection. Transplant Proc. 1988 Aug;20(4):614-6. PubMed PMID: 3136570.

124:  Hammerer P, Krämer-Hansen H, Kremer B, Henne-Bruns D, Klöppel G, Arndt R, Huland H. Aspiration cytology of liver transplants. Transplant Proc. 1988 Aug;20(4):640-1. PubMed PMID: 3043824.

125:  Arndt R, Heinzer H, Hammerer P, Huland H, Löhning T, Krämer-Hansen H. Identification of virus DNA in kidney transplants by fine-needle aspiration biopsy. Transplant Proc. 1988 Aug;20(4):581-3. PubMed PMID: 3043804.

126:  Hammerer P, Arndt R, Krämer-Hansen H, Huland H, Klosterhalfen H. Consecutive selective aspiration cytology of renal cortex and renal medulla in kidney transplants. Transplant Proc. 1988 Aug;20(4):577-8. PubMed PMID: 3043802.

127:  Arndt R, Hammerer P, Huland E, Krämer-Hansen H, Huland H. Treatment of acute cellular rejection in renal transplantation patients on ciclosporin with antithymocyte globulin. Urol Int. 1988;43(3):139-44. PubMed PMID: 3051619.